The gold industry standard for risk and cost of drug and vaccine development revisited

Esther Pronker; Tamar Weenen; Harry Commandeur; Ab Osterhaus; Eric Claassen

doi:10.1016/j.vaccine.2011.06.051

The gold industry standard for risk and cost of drug and vaccine development revisited

Esther Pronker
, Tamar Weenen
, Harry Commandeur
, Ab Osterhaus
, Eric Claassen

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

Abstract

Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication: Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? (C) 2011 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	5846-5849
Number of pages	4
Journal	Vaccine
Volume	29
Issue number	35
DOIs	https://doi.org/10.1016/j.vaccine.2011.06.051
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-04-27-01

Access to Document

10.1016/j.vaccine.2011.06.051

http://hdl.handle.net/1765/31307

Cite this

@article{c348dc3cc6d043b1893ef7456f7b1163,

title = "The gold industry standard for risk and cost of drug and vaccine development revisited",

abstract = "Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US\$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22\% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication: Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7\% to 78\% and investments calculations span US\$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? (C) 2011 Elsevier Ltd. All rights reserved.",

author = "Esther Pronker and Tamar Weenen and Harry Commandeur and Ab Osterhaus and Eric Claassen",

year = "2011",

doi = "10.1016/j.vaccine.2011.06.051",

language = "English",

volume = "29",

pages = "5846--5849",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "35",

}

TY - JOUR

T1 - The gold industry standard for risk and cost of drug and vaccine development revisited

AU - Pronker, Esther

AU - Weenen, Tamar

AU - Commandeur, Harry

AU - Osterhaus, Ab

AU - Claassen, Eric

PY - 2011

Y1 - 2011

N2 - Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication: Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? (C) 2011 Elsevier Ltd. All rights reserved.

AB - Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication: Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? (C) 2011 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2011.06.051

DO - 10.1016/j.vaccine.2011.06.051

M3 - Article

C2 - 21722688

SN - 0264-410X

VL - 29

SP - 5846

EP - 5849

JO - Vaccine

JF - Vaccine

IS - 35

ER -

The gold industry standard for risk and cost of drug and vaccine development revisited

Abstract

UN SDGs

Research programs

Access to Document

Fingerprint

Cite this